Antibody-directed urokinase: a specific fibrinolytic agent

Area of Science:

• Biochemistry
• Immunology
• Thrombosis Research

Background:

• Fibrinolysis is crucial for dissolving blood clots.
• Urokinase is a fibrinolytic enzyme, but its systemic administration can lead to bleeding complications.
• Targeted delivery of fibrinolytic agents can improve efficacy and reduce side effects.

Purpose of the Study:

• To develop a novel fibrinolytic agent with enhanced specificity and activity.
• To conjugate urokinase to a fibrin-specific monoclonal antibody.
• To evaluate the fibrinolytic efficacy and specificity of the conjugate in vitro.

Main Methods:

• A monoclonal antibody was generated against a synthetic peptide of human fibrin beta chain.
• Urokinase was covalently coupled to the fibrin-specific monoclonal antibody.
• In vitro fibrinolysis assays were performed comparing the conjugate to unmodified urokinase.
• The effect of human fibrinogen on conjugate activity was assessed.

Main Results:

• The urokinase-antifibrin conjugate demonstrated retained antibody binding specificity.
• The conjugate exhibited a 100-fold increase in fibrinolytic activity compared to urokinase alone.
• Fibrinogen at plasma concentrations did not inhibit the conjugate's fibrinolytic properties.

Conclusions:

• Covalent coupling of urokinase to a fibrin-specific antibody creates a potent and targeted fibrinolytic agent.
• This targeted approach significantly enhances fibrinolysis in vitro.
• The conjugate shows potential for improved thrombolytic therapy with reduced off-target effects.